Literature DB >> 24213578

The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.

J Sun1, S Mohlin2, A Lundby3, J U Kazi1, U Hellman4, S Påhlman2, J V Olsen3, L Rönnstrand1.   

Abstract

PI3-kinase has a crucial role in transformation mediated by the oncogenic c-Kit mutant D816V. In this study, we demonstrate that the c-Kit/D816V-mediated cell survival is dependent on an intact direct binding of PI3-kinase to c-Kit. However, mutation of this binding site had little effect on the PI3-kinase activity in the cells, suggesting that c-Kit/D816V-mediated cell survival is dependent on PI3-kinase but not its kinase activity. Furthermore, inhibition of the lipid kinase activity of PI3-kinase led only to a slight inhibition of cell survival. Knockdown of the predominant PI3-kinase isoform p110δ in c-Kit/D816V-expressing Ba/F3 cells led to reduced cell transformation both in vitro and in vivo without affecting the overall PI3-kinase activity. This suggests that p110δ has a lipid-kinase-independent role in c-Kit/D816V-mediated cell transformation. We furthermore demonstrate that p110δ is phosphorylated at residues Y524 and S1039 and that phosphorylation requires an intact binding site for PI3-kinase in c-Kit/D816V. Overexpression of p110δ carrying the Y523F and S1038A mutations significantly reduced c-Kit/D816V-mediated cell survival and proliferation. Taken together, our results demonstrate an important lipid-kinase-independent role of p110δ in c-Kit/D816V-mediated cell transformation. This furthermore suggests that p110δ could be a potential diagnostic factor and selective therapeutic target for c-Kit/D816V-expressing malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213578     DOI: 10.1038/onc.2013.479

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.

Authors:  Oscar Lindblad; Julhash U Kazi; Lars Rönnstrand; Jianmin Sun
Journal:  Cell Mol Life Sci       Date:  2015-06-04       Impact factor: 9.261

Review 2.  SOCS6 is a selective suppressor of receptor tyrosine kinase signaling.

Authors:  Nuzhat N Kabir; Jianmin Sun; Lars Rönnstrand; Julhash U Kazi
Journal:  Tumour Biol       Date:  2014-08-30

3.  Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.

Authors:  Tianfeng Li; Yi Deng; Yu Shi; Ruijun Tian; Yonglong Chen; Lin Zou; Julhash U Kazi; Lars Rönnstrand; Bo Feng; Sun On Chan; Wai Yee Chan; Jianmin Sun; Hui Zhao
Journal:  Oncogene       Date:  2018-07-16       Impact factor: 9.867

Review 4.  Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.

Authors:  Hengning Ke; Julhash U Kazi; Hui Zhao; Jianmin Sun
Journal:  Cell Biosci       Date:  2016-10-18       Impact factor: 7.133

5.  XK-related protein 5 (XKR5) is a novel negative regulator of KIT/D816V-mediated transformation.

Authors:  Jianmin Sun; Tine Thingholm; Peter Højrup; Lars Rönnstrand
Journal:  Oncogenesis       Date:  2018-06-18       Impact factor: 7.485

6.  Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.

Authors:  Timothy J Thauland; Laurence Pellerin; Robert S Ohgami; Rosa Bacchetta; Manish J Butte
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

7.  Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently.

Authors:  Shaoting Zhang; Liangying Zhang; Zongying Jiang; Yue Guo; Hui Zhao; Jianmin Sun
Journal:  Biochem Biophys Rep       Date:  2021-03-02

8.  FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.

Authors:  Rohit A Chougule; Julhash U Kazi; Lars Rönnstrand
Journal:  Oncotarget       Date:  2016-03-01

9.  Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

Authors:  O Lindblad; E Cordero; A Puissant; L Macaulay; A Ramos; N N Kabir; J Sun; J Vallon-Christersson; K Haraldsson; M T Hemann; Å Borg; F Levander; K Stegmaier; K Pietras; L Rönnstrand; J U Kazi
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

10.  Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib.

Authors:  Guangrong Zhu; Jun Shi; Shaoting Zhang; Yue Guo; Ling Huang; Hui Zhao; Yideng Jiang; Jianmin Sun
Journal:  Cell Biosci       Date:  2020-02-12       Impact factor: 7.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.